## CMS Reminds Physicians of HIPAA X12 Deadline

BY MARY ELLEN SCHNEIDER

hysicians have a little more than 2 years to complete their transition to new HIPAA X12 standards for submitting administrative transactions electronically, according to Medicare of-

As of Jan. 1, 2012, physicians and all other entities covered under HIPAA (Health Insurance Portability and Accountability Act) will be required to use the HIPAA X12 version 5010 format when submitting claims, receiving remittances, and sending claim status or eligibility inquiries electronically. The new standard replaces the version 4010A1 currently in use. The change will affect dealings not only with Medicare, but also with all private payers.

The Medicare fee-for-service program will begin its own system testing next year and will begin accepting administrative transactions using the 5010 version as of Jan. 1, 2011. Throughout 2011, the Centers for Medicare and Medicaid Services will accept both the 5010 and 4010A1 versions. However, beginning on Jan. 1, 2012, only transactions submitted using the 5010 version will be accepted.

During a recent conference call to update providers, officials at the Centers for Medicare and Medicaid Services urged physicians not to wait until the last minute to make the transition to the new format

'There's no room to delay. We cannot possibly convert all of the Medicare trading partners at the 11th hour," said Christine Stahlecker, who is director of the division of medicare billing procedures in the CMS Office of Information Services.

The switch is necessary, according to the CMS, because the 4010A1 version is outdated. For example, the industry currently relies heavily on companion guides to implement the standards, which limits their value. The new version includes some new functions aimed at improving claims processing, such as resolving ambiguities in the situational rules and providing more consistency across transactions.

But Medicare officials urged physicians to analyze the new version carefully prior to implementation. Billing software will need to be updated, and business processes may need to be changed as well. "There are real changes in these formats," Ms. Stahlecker said.

A comparison of the current and new formats can be viewed online at www. cms.hhs.gov/ElectronicBillingEDITrans/ 18\_5010D0.asp.

INDEX OF

**ADVERTISERS** 

33-34

61

26a-26b


41

# Treat your pati Discounts Treat yourself. Treat your patient.

#### **Register Now for the Fifth Annual Chicago Supportive Oncology Conference**

Gain important insight about practical management issues in palliative and supportive care. Learn to:

- Identify and treat depression and other psychiatric conditions in the patient with cancer
- Identify cancer survivors at risk for anorexia cachexia, and other nutritional deficits and incorporate a nutritional plan into their overall care plan
- Recognize neurotoxicities associated with cancer treatments and strategies for management
- Describe and address issues in cancer pain management, including management of addictive disease and hyperalgesia and opioid-induced pain
- Summarize the role of complementary therapies in supportive cancer care, particularly acupuncture and mind-body interventions
- Explain the effects of cancer treatments on sexuality and fertility and the current approaches for their management
- Provide mentorship for colleagues in integrating supportive and palliative care into daily clinical practice
- Identify effective strategies to improve communication issues surrounding the cancer diagnosis, including prognosis, talking with children, and cultural sensitivity
- Describe palliative measures in advanced disease, specifically lung cancer and liver metastases
- Integrate evidence-based management of cancer-related mucositis, refractory nausea and vomiting, and diarrhea into a patient's plan of care
- Evaluate current clinical data on growth factor support, cardiovascular complications with VEGF inhibitors, and skin complications of targeted therapies





#### Register now and SAVE

www.supportiveoncology.net/chicago

### Eisai Inc. and Pfizer Inc. Aricept Namenda Bystolic Savella **Eli Lilly and Company**

Corporate

Wyeth Pharmaceuticals Inc.

Daiichi Sankvo. Inc.

**Almond Board of California** 

Amylin Pharmaceuticals, Inc.

Cephalon, Inc.

Comcast

**Endo Pharmaceuticals** 58-60 Forest Laboratories, Inc. 8a-8b 11-14 19-23 45-49 Humalog 63-64 Merck & Co., Inc. 42a-42b. 43 Novo Nordisk Inc. 15-16 Pfizer Inc. 3-4 Helpful Answers PriCara NUCYNTA 34a-34d, 35 Sanofi Pasteur Inc. Schering-Plough HealthCare Products, Inc. 55 Takeda Pharmaceuticals North America, Inc. 51-52 VISA